Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients

Diseases of the Colon and Rectum

Volumn 41, Issue 1, 1998, Pages 68-74

  Fu, Chuan Gang ^b   Tominaga, Osamu ^a   Nagawa, Hirokazu ^a,c   Nita, Marcelo Eidi ^a   Masaki, Tadahiko ^a   Ishimaru, Gosei ^a   Higuchi, Yoshiki ^a   Tsuruo, Takashi ^a   Muto, Tetsuichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Carcinoma; p21 WAF1; p53; Radiosensitivity; Rectum

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CLINICAL FEATURE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT SELECTION; PREDICTION; PREOPERATIVE EVALUATION; RADIOSENSITIVITY; RECTUM CANCER; STATISTICAL ANALYSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREOPERATIVE CARE; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; RECTAL NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031963120     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02236898     Document Type: Article

References (23)

1. Sause WT, Pajak TF, Noyes RD, et al. Evaluation of preoperative radiation therapy in operable colorectal cancer. Ann Surg 1994;220:668-75.
2. Holm T, Cedermark B, Rutqvist LE. Local recurrence of rectal adenocarcinoma after "curative" surgery with and without preoperative radiotherapy. Br J Surg 1994;81: 452-5.
3. Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced carcinoma: results of a prospective, randomized trial. Dis Colon Rectum 1994;37:1205-14.
4. Lingareddy V, Mohiuddin M, Marks G. The importance of patient selection for adjunctive postoperative radiation therapy for cancer of the rectum. Cancer 1994;73: 1805-10.
5. Fan S, EL-Deiry S, Boe I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54:5824-30.
6. Tsang NM, Nagasawa H, Li C, Little JB. Abrogation of p53 function by transfection of HPV 16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 1995;10:2403-8.
7. Namba H, Hara T, Tukazaki T, et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/CIP1 pathway in human thyroid cells. Cancer Res 1995;55: 2075-80.
8. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993;362:847-52.
9. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266: 807-10.
10. Xia F, Wang X, Wang YH, et al. Altered p53 status correlates with differences in sensitivity to radiation induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995;55:12-5.
11. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
12. Brugarolas J, Chandrasekaran C, Gordor JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377: 552-7.
13. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
14. Japanese Research Society for Cancer of the Colon and Rectum. Criteria for histopathological evaluation of radiotherapy effect. In: General rules for clinical and pathological studies on cancer of the colon, rectum and anus. 5th ed. Tokyo: Kanehara & Co., 1994:42.
15. Remvikos Y, Tominaga O, Hammel P, et al. Increased p53 protein content of colorectal tumors correlates with poor survival. Br J Cancer 1992;66:758-64.
16. Tominaga O, Hamelin R, Trouvat V, et al. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 1993;8:2653-8.
17. Tominaga O, Salmon RJ, Laurent-Puig P. Gene TP53 et cancers digestifs. Gastroenterol Clin Biol 1993;17: 187-96.
18. Tominaga O, Hamelin R, Remvikos Y, Salmon RJ, Thomas G. p53 from basic research to clinical application. Crit Rev Oncog 1992;3:257-82.
19. EL-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
20. Bae I, Fan S, Bhatia KB, Kohn KW, Fornace AJ, O'Connor PM. Relationships between G1 arrest and stability of the p53 and p21 CIP1/WAF1 proteins following irradiation of human lymphoma cells. Cancer Res 1995;55:2387-93.
21. Takiguchi N, Sarashina N, Saitoh N, et al. Histopathological and roentogenological study on effects of preoperative irradiation therapy for rectal cancer. J Jpn Soc Coloproctol 1993;93:599-606.
22. Fukunaga-Johnson N, Ryan JJ, Wicha M, Nunez G, Clarke MF. Bcl-2 protects murine erytholeukemia cells from p53-dependent and independent radiation-induced cell death. Carcinogenesis 1995;16:1761-7.
23. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9:451-73.